These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 35501296)
1. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model. Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296 [TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Lin SM; Yang SH; Liang CC; Huang HK Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384 [TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Poly TN; Islam MM; Yang HC; Wu CC; Li YJ Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272 [TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study. Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930 [TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes. Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941 [TBL] [Abstract][Full Text] [Related]
6. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040 [TBL] [Abstract][Full Text] [Related]
7. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study. Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y Bone; 2020 Oct; 139():115502. PubMed ID: 32593677 [TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Chen CH; Lin CL; Kao CH Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609 [TBL] [Abstract][Full Text] [Related]
9. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Seo SI; Park CH; You SC; Kim JY; Lee KJ; Kim J; Kim Y; Yoo JJ; Seo WW; Lee HS; Shin WG Gut; 2021 Nov; 70(11):2066-2075. PubMed ID: 33975868 [TBL] [Abstract][Full Text] [Related]
10. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756 [TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis. Hussain S; Siddiqui AN; Habib A; Hussain MS; Najmi AK Rheumatol Int; 2018 Nov; 38(11):1999-2014. PubMed ID: 30159775 [TBL] [Abstract][Full Text] [Related]
12. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499 [TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083 [TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Corley DA; Kubo A; Zhao W; Quesenberry C Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792 [TBL] [Abstract][Full Text] [Related]
16. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus. Ock M; Lee S; Kim H J Clin Pharm Ther; 2022 Jul; 47(7):1028-1035. PubMed ID: 35257383 [TBL] [Abstract][Full Text] [Related]
17. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Targownik LE; Lix LM; Leung S; Leslie WD Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262 [TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study. Park JH; Song YM; Jung JH; Han K Bone; 2020 Jun; 135():115306. PubMed ID: 32126312 [TBL] [Abstract][Full Text] [Related]
19. Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Fusaro M; D'Arrigo G; Pitino A; Iervasi G; Tentori F; Robinson B; Aghi A; Bieber B; Mccullogh K; Fabris F; Plebani M; Giannini S; Gallieni M; Tripepi G J Bone Miner Res; 2019 Dec; 34(12):2238-2245. PubMed ID: 31365145 [TBL] [Abstract][Full Text] [Related]
20. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]